Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YEEHAW CANDIDATES -- Ignore unavailable to you. Want to Upgrade?

To: Galirayo who wrote (14438)	1/13/2006 11:30:02 AM
From: Augustus Gloop	Read Replies (1) \| Respond to of 23958

11:19 NVAX Novavax company finished presenting at the University of Maryland avian flu conference (4.58 -0.04) The co's C.E.O Rahul Singhvi just finished speaking at the conference. In his speech he highlighted the three main issues of the emerging strain, immunogenicity, and surge capacity. During his speech he focuses on how NVAX is working on the ability to solve all three problems and believes they have a solution. Using the co's V.L.P's with the correct adjuvant they think they could have matched the strain, and cut the vaccine to one dose to one. The C.E.O also talked about his idea for the use of disposable cell culture centers which are much more cost effective and have a shorter construction time, incase there is a large flue outbreak.